Cefalogen

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cefalogen

Quick Facts

Property Description
Active ingredient Ceftriaxone
Form Sterile powder for injection
Pharmacological class Third-generation cephalosporin antibiotic
General purpose Clearing serious bacterial infections
Origin Semisynthetic

What Type of Antibiotic is Cefalogen?

Cefalogen is a potent, prescription-only medication whose active component is Ceftriaxone. It is classified as an antibiotic and, more specifically, belongs to the third-generation cephalosporin group, which are chemical compounds designed to target and eliminate harmful bacteria. These drugs are fundamentally a type of beta-lactam antibiotic, defined by a core chemical structure that is essential for their mechanism of action, and this class is recognized for its efficacy against resistant organisms.

This classification is crucial because Ceftriaxone represents an evolution in antibacterial agents, offering enhanced stability against many bacterial defense enzymes compared to older cephalosporins. This semisynthetic compound is used primarily to fight serious bacterial infections and is clinically recognized for its reliable action across diverse patient groups. It serves as a robust, broad-spectrum tool, often chosen for complicated systemic illnesses such as sepsis or severe pneumonia.


Cefalogen's Composition and General Purpose

Cefalogen is a single active ingredient product, supplied as a sterile powder for injection that must be mixed with a diluent before administration. The main ingredient is Ceftriaxone (typically as the disodium salt), an entity designed to be highly effective when delivered directly into the patient's system.

This particular dosage form is necessary because Ceftriaxone is poorly absorbed when taken orally, necessitating parenteral administration (by injection) to ensure the full, active dose reaches the bloodstream rapidly. The general purpose of this antibacterial agent is bactericidal; it functions by directly killing susceptible bacteria through the targeted inhibition of bacterial cell wall synthesis, ultimately clearing the infection. Ceftriaxone is often differentiated from other injectable antibiotics by its extended half-life, a property that allows for less frequent parenteral administration in clinical settings.

What side effects are possible with Cefalogen?

Possible Side Effects and Safety Information

The safety profile for Ceftriaxone, the active component of Cefalogen, is established by regulatory documents that classify potential adverse reactions by frequency and physiological system. This information defines the essential risks associated with the medicine.

Adverse Reaction Classification

Official labeling classifies effects based on their documented rate of occurrence in clinical use:

Frequency Category Examples of Documented Effects
Common (1% to <10%) Diarrhea, rash, eosinophilia, leukopenia, and increases in hepatic enzymes.
Uncommon (0.1% to <1%) Headache, dizziness, nausea, vomiting, pruritus, and localized injection site reactions or phlebitis.
Rare (0.01% to <0.1%) Seizures/convulsions, pseudomembranous colitis, haematuria, and urticaria.
Not Known Anaphylactic shock, haemolytic anaemia, and severe cutaneous adverse reactions (SCARs).

Serious Safety Constraints

The most distinctive regulatory constraint is the absolute prohibition against the simultaneous administration of Cefalogen with calcium-containing solutions (including IV fluids) in all patients, due to the risk of potentially fatal ceftriaxone-calcium salt precipitation in the organs. Serious adverse reactions explicitly documented include life-threatening anaphylactic shock, severe systemic reactions like haemolytic anaemia, and C. difficile-associated diarrhea.

Population and Exposure Considerations

Specific safety warnings apply to certain groups. The medicine is contraindicated in hyperbilirubinaemic newborns due to the risk of kernicterus. Patients who are older adults or who have documented kidney impairment are overrepresented in reports of serious neurological adverse reactions, such as encephalopathy and convulsions. Furthermore, certain effects, like the Jarisch-Herxheimer reaction, may occur shortly after treatment initiation for specific infections, as noted in the official prescribing information.

Overdose and Emergency Response

Cefalogen Overdose and When to Seek Help

Overdose with Cefalogen (Ceftriaxone) may lead to documented presentations such as nausea, vomiting, and diarrhoea. More severe outcomes and risks to physiological systems are associated with high drug concentrations, requiring mandated emergency action.

Documented Overdose Manifestations and Risks

System Documented Manifestation
Neurological High plasma levels are associated with serious adverse reactions, including encephalopathy, convulsions (seizures), myoclonus, and non-convulsive status epilepticus.
Renal/Biliary The formation of Ceftriaxone-calcium precipitates may occur in the gallbladder or kidneys, potentially leading to urolithiasis and subsequent post-renal acute renal failure.

Emergency Action and Help-Seeking Requirements

In all suspected cases of overdose, immediate medical attention is required, as mandated by regulatory authorities. If a severe reaction such as anaphylactic shock occurs, immediate emergency counter-measures must be initiated, and the drug must be discontinued. Regulatory documents state that no specific antidote is available for Ceftriaxone overdose. Therefore, treatment is explicitly defined as symptomatic and supportive. Regulatory information also notes that the drug is not effectively removed by haemodialysis or peritoneal dialysis. Severe renal impairment increases the risk of neurological toxicity. Additionally, neonates (premature or hyperbilirubinaemic) are at risk of kernicterus due to the effects of high drug levels.

Therapeutic Uses of Cefalogen

Cefalogen (Ceftriaxone) is commonly used for managing serious bacterial illnesses and the symptoms that interfere with daily functioning they may cause across multiple critical body systems. The medication may assist with the elimination of the infectious source, and contributes to easing the acute, disruptive symptoms. This drug is indicated for a broad range of severe infections.

This antibiotic is considered relevant in conditions presenting with acute episodes like sepsis and bacterial meningitis. It is also applied to manage symptoms of complicated infections in the lower respiratory tract (severe pneumonia), the abdomen, and bone and joints. This application assists with managing infection in complex anatomical sites, which contributes to easing acute, localized symptom burden.

The focused use of Cefalogen in these critical scenarios may be part of symptomatic management and may assist with maintaining functional stability.

“This application assists with managing infection in complex anatomical sites, which contributes to easing acute, localized symptom burden.”


Quick Fact: Support for Systemic Distress Cefalogen is commonly used when symptoms related to systemic imbalance and heightened physiological activity become more noticeable, particularly in hospital-based care and surgical settings where short-term symptomatic assistance is needed.

This focused application is relevant for easing symptoms in defined high-risk situations, and may assist with reducing the risk of infection following surgery (surgical prophylaxis).

Regulatory References

  1. FDA Approved Drug Products: Ceftriaxone for Injection

Eligibility and Restrictions for Use

Cefalogen (Ceftriaxone) eligibility is strictly defined by official regulatory documentation, outlining populations for whom use is established, restricted, or absolutely prohibited.


Populations for Whom Use is Contraindicated

The medicine is contraindicated and must not be used by patients with a known hypersensitivity to Ceftriaxone, to any other cephalosporin antibiotic, or to any excipient. Use is also strictly prohibited in specific neonatal subgroups (mathbfleq 28 days) who are receiving intravenous calcium-containing solutions. Similarly, the medicine is contraindicated in hyperbilirubinemic or premature neonates (up to 41 weeks postmenstrual age).


Restricted Eligibility and Limitations ️

Use is generally established in adults and older adults. Eligibility is restricted for adult patients with concurrent severe renal and hepatic impairment, requiring a formal limitation on the maximum daily dosage. Caution is formally recommended for patients with a history of penicillin allergy or colitis. For pregnancy, use is conditional and only permitted if the potential benefit justifies the potential risk. Caution is recommended when the medicine is administered to a nursing woman.

What should I know about interactions with other medicines?

Cefalogen (Ceftriaxone) exhibits specific, documented interaction patterns primarily concerning its intravenous administration. The most critical restriction involves co-administration with calcium-containing solutions, which is formally classified as a contraindicated combination in neonates 28 days of age or younger due to the risk of ceftriaxone-calcium salt precipitation. Simultaneous intravenous administration of Cefalogen and any calcium-containing solution is prohibited in all age groups. For non-neonatal patients, regulatory documents require a separation interval: intravenous Cefalogen and intravenous calcium-containing products should not be administered within 48 hours of each other.

The drug’s official profile also details pharmacodynamic interactions. Co-administration with oral anticoagulants, such as Warfarin, may officially increase the anticoagulant effect, leading to documented alterations in Prothrombin Time (PT) and International Normalized Ratio (INR). Furthermore, an additive organ toxicity caution exists with other nephrotoxic agents, including the Aminoglycosides class. Physical incompatibility restrictions apply to several agents, including Vancomycin, Amsacrine, and Fluconazole, which must not be mixed or co-infused in the same line. A population-specific interaction is noted in hyperbilirubinemic neonates related to the displacement of bilirubin from serum albumin.

Mechanism of Action

How Cefalogen Works

Cefalogen acts within domains involving enzyme-mediated signaling by utilizing its core beta-lactam structure. This ring is the crucial component that mimics the natural substrate of key bacterial enzymes, initiating the subsequent cascade.


The drug engages mechanisms that influence cell wall synthesis by binding irreversibly to penicillin-binding proteins (PBPs) located within the bacterial cell wall. This essential molecular step modifies the early part of the cell wall synthesis pathway.


Cefalogen initiates a signaling sequence that leads to downstream effects by preventing the PBPs from performing the final transpeptidation (cross-linking) of peptidoglycan chains. This alters pathway activity in the bacterial system by halting the peptidoglycan cross-linking step. The inhibition of cell wall construction leads to a physiological consequence that results in the weakening and eventual lysis of the bacterial cell, causing the direct elimination of susceptible microorganisms through cell disruption.

Dosage and Administration Information

How to Use Cefalogen: Administration Guidelines

Cefalogen (Ceftriaxone) is a sterile powder that is administered exclusively via parenteral routes, meaning it must be professionally injected into the body. Its use is established via either intravenous (IV) injection or IV infusion, or through deep intramuscular (IM) injection.


Administration Scope

Instruction Standard Guideline
Route of Administration IV (slow injection or infusion) or IM injection.
Standard Adult Dose Typically 1 g to 2 g daily, with a maximum dose up to 4 g for severe infections.
Frequency Pattern Primarily administered once daily (q24hr); doses exceeding 2 g daily may be given twice daily (q12hr).
Preparation Requires reconstitution using specific, compatible diluents. IV use requires calcium-free solutions.

Procedural Constraints and Special Rules

The correct administration of Cefalogen requires adherence to specific label-based constraints. The powder must be properly reconstituted before use. For IV use, the reconstituted solution must not be mixed with, or administered simultaneously through the same line as, any solutions containing calcium, due to the risk of precipitation. For IM administration, reconstitution often involves a 1% lidocaine solution, and this specific preparation is strictly for intramuscular use only and must never be given intravenously.

Treatment duration is typically guided by the infection, commonly ranging from 4 to 14 days, and is often continued for at least 48 to 72 hours after fever has resolved to ensure clearance of the bacterial infection. Dosage limitations exist for specific patient groups; for instance, the maximum dose should not exceed 2 g daily for patients with severe combined renal and hepatic impairment.

Recent Clinical Evidence

Research evidence / Overview of studies for Cefalogen

Evidence for Use in Treating Life-Threatening Systemic Infections

Research exploring the use of Cefalogen in systemic conditions relies primarily on Randomized Controlled Trials (RCTs), where its use was compared to other standard antibiotics. These core data are synthesized in comprehensive Systematic Reviews and Meta-analyses. The studies included patients with high-risk infections, such as those with sepsis or bacterial meningitis, and monitored rates of Microbiological Eradication or non-eradication. Studies also examined outcomes related to Mortality up to 90 days after treatment.

What remains uncertain is the consistency of findings for specific subgroups, such as certain types of Bloodstream Infections (BSI), where evidence is limited due to modest sample sizes in some research. The long-term effects are not fully established and long-term outcomes are not well characterized.


Evidence for Use in Organ-Specific Severe Infections

Cefalogen was evaluated in trials addressing complicated infections that may result in systemic or functional imbalance, such as Community-Acquired Pneumonia (CAP) in hospitalized patients. These research settings involved comparing Cefalogen to established care. Outcomes linked to inflammatory or irritative states, such as the rate of Microbiological Eradication at a pre-defined Test-of-Cure visit, was studied for a range of organ-specific conditions.

The existing research includes older trials where the evidence quality varies across studies, particularly concerning the descriptions of blinding and randomisation methods. This suggests that certainty remains low regarding the direct comparability of some older findings. Additionally, follow-up durations were limited to short-term assessments after the end of treatment.


Evidence for Use in Surgical Prophylaxis (Infection Prevention)

Surgical Prophylaxis research focuses on study objectives related to the prevention of post-operative infections, and Cefalogen was studied for this use in numerous Randomized Controlled Trials. The research examined outcomes related to the incidence of new infections, such as Surgical Site Infection (SSI).

A key research limitation is that comparative evidence is lacking against inactive treatments for many surgical procedures. The available data is focused on short- to intermediate-term outcomes (up to 90 days), and long-term infection rates after that mark are not fully established.

Key Studies & References Label: CEFTRIAXONE injection, powder, for solution - DailyMed (FDA Monograph)

Frequently Asked Questions (FAQ)

Common questions about Cefalogen (FAQ)

Q: Can Cefalogen cause liver or kidney-related side effects?

A: Regulatory documents indicate that transient increases in liver enzyme values have been reported. Rare cases of serious liver issues, such as hepatitis or cholestatic jaundice, are also noted in official product information. For the kidneys, specific warnings exist for patients who already have severe combined renal and hepatic (liver) impairment.

Q: What kind of infections does Cefalogen generally not treat effectively?

A: Cefalogen is classified as an antibacterial agent, meaning it is specifically designed to fight bacteria and is not effective against viral infections, such as the common cold or influenza. Its effectiveness may be limited if the bacteria causing the infection demonstrate resistance to this antibiotic class.

Q: Does Cefalogen interact with hormonal birth control methods?

A: Official information indicates that this antibiotic, like others, may reduce the effectiveness of estrogen-containing birth control methods. This reduction in effectiveness could potentially increase the risk of pregnancy. Concerns about effectiveness should be discussed with a healthcare professional.

Q: Is it possible for Cefalogen to cause confusion or dizziness?

A: Official documentation lists dizziness as an uncommon side effect reported by patients. More severe neurological reactions, such as convulsions and encephalopathy (brain dysfunction), have been reported in rare cases, particularly among older adults or those with impaired kidney function.

Q: Are there any known interactions between Cefalogen and alcohol consumption?

A: Unlike some antibiotics, Cefalogen does not carry a specific formal warning in official labels against consuming alcohol. While there is no formal warning, patients should consider discussing alcohol consumption with a healthcare provider during treatment, as is typical with many medications.

Q: Is Cefalogen used to treat sexually transmitted diseases (STDs)?

A: Yes, regulatory and health authority treatment guidelines recommend Cefalogen (Ceftriaxone) for the treatment of uncomplicated gonorrhea, a sexually transmitted infection. It may also be used in certain treatment protocols for other specific infections as guided by professional standards.

Q: How long after stopping Cefalogen can side effects like diarrhea still occur?

A: Diarrhea is a common side effect of many antibiotics. The severe form known as C. difficile-associated diarrhea (CDAD) can occur during treatment or even up to two months or more after treatment with Cefalogen has been stopped. Patients experiencing severe or persistent diarrhea post-treatment are advised to seek medical review.

Q: Is it true that Cefalogen can sometimes cause gallstones or biliary sludge?

A: Yes, official documentation notes that reversible precipitates of ceftriaxone-calcium salt have been occasionally observed in the gallbladder. This is commonly referred to as biliary sludge or pseudolithiasis; however, these formations are generally reversible and may resolve upon discontinuation of the medication.

Q: Does Cefalogen have a long half-life compared to other antibiotics?

A: Yes, the active ingredient in Cefalogen is characterized by an extended elimination half-life, typically ranging from 6 to 9 hours. This longer half-life is a key feature that allows the medication to be administered once daily in most clinical applications.

Q: Is there a risk of Cefalogen interacting with calcium-containing solutions?

A: Yes, there is a serious risk of precipitation of ceftriaxone-calcium salts forming in the bloodstream. The official product information specifies that simultaneous intravenous administration of Cefalogen and any calcium-containing solution is formally contraindicated in all patient groups.

Q: What are the signs of a blood disorder side effect from Cefalogen?

A: Reported blood disorders include haemolytic anaemia (unusual destruction of red blood cells), leukopenia (low white blood cells), and eosinophilia (increased white blood cells). Unusual symptoms, such as severe fatigue, unexplained weakness, bruising, or bleeding, are noted as potential indicators that should be reviewed by a professional.

Q: Can Cefalogen interact with blood thinning medications?

A: Yes, Cefalogen may increase the effect of oral anticoagulants such as Warfarin. This interaction can alter blood clotting parameters like the INR and may increase the risk of bleeding. Official warnings state that co-administration may require close professional monitoring of blood clotting parameters.

Q: Is Cefalogen an effective treatment for bacterial meningitis?

A: Yes, Cefalogen (Ceftriaxone) is officially indicated in many major jurisdictions for the treatment of bacterial meningitis in both adults and children. This is due to its ability to reach effective concentrations in the cerebrospinal fluid.

Q: Why might a person feel tired or weak while receiving Cefalogen?

A: Official documentation lists malaise (a general feeling of discomfort or weakness) as an uncommon side effect. Additionally, if the patient develops the rare but serious side effect of haemolytic anaemia, it can also cause unusual weakness and fatigue.

Q: Can taking Cefalogen cause a secondary fungal infection, like thrush?

A: As a broad-spectrum antibiotic, Cefalogen can disrupt the normal balance of microorganisms in the body, which may lead to the overgrowth of non-susceptible organisms. This process can result in secondary infections, including fungal infections like candidiasis (thrush).

Q: What is the scientific evidence for Cefalogen's penetration into the central nervous system?

A: Regulatory documents explicitly state that Ceftriaxone penetrates the meninges (the protective layers around the brain and spinal cord). It achieves therapeutically relevant concentrations in the cerebrospinal fluid, which confirms its suitability for treating central nervous system infections.

Q: Does Cefalogen have activity against Pseudomonas aeruginosa bacteria?

A: Official information generally describes Cefalogen's action against a broad spectrum of bacteria. It does exhibit some documented activity against Pseudomonas aeruginosa. This activity is noted in the official spectrum of activity.

Q: Is Cefalogen a common alternative for patients with certain drug resistances?

A: Cefalogen is a third-generation cephalosporin, valued for its enhanced stability against certain bacterial defense enzymes known as beta-lactamases. This property makes it a key and common choice in clinical settings where resistance to older, first- or second-line antibiotics is known or suspected.

Q: Does Cefalogen have any effect on blood sugar levels, especially for diabetics?

A: Cefalogen may interfere with certain laboratory tests, potentially causing false-positive results for sugar in the urine (glycosuria). Official warnings advise patients with diabetes who check their urine sugar to be aware of this possibility.

Q: How quickly should I expect Cefalogen to start clearing up the infection?

A: Studies indicate that for many infections, patients may begin to see signs of improvement, such as reduced fever, within 24 to 48 hours of starting treatment. The full course of medication should be administered as prescribed by a healthcare professional.

Q: Is feeling mildly nauseous or having a headache a normal side effect of Cefalogen?

A: Headache and nausea are listed as uncommon side effects in official product information, meaning they are reported by less than 1% of patients. While they are documented effects, any concerns regarding side effects should be discussed with a healthcare professional.

Q: Does Cefalogen affect gut flora, and is it recommended to take probiotics?

A: As an antibiotic, Cefalogen can disrupt the natural balance of bacteria in the gut. While official drug labels focus on serious risks like C. difficile diarrhea, they do not universally recommend or prohibit probiotics. The use of probiotics alongside this medication should be addressed with a healthcare provider.

Q: What steps are taken to prevent pain during the intramuscular injection of Cefalogen?

A: To help minimize the pain associated with a deep intramuscular injection, the official guidelines state that the powder for IM use is often reconstituted using a lidocaine solution. This specific preparation is only for intramuscular use and must never be administered intravenously.

Q: What research has been done on the long-term effects of Cefalogen use?

A: The majority of published research, including clinical trials for its indications, focuses on short-term outcomes during and immediately after the typical treatment duration of 4 to 14 days. Official research summaries often state that long-term effects are not fully established or that follow-up durations were limited.

Q: Is it true Cefalogen is sometimes given as a single dose?

A: Yes, Cefalogen is sometimes used as a single dose for specific, approved clinical applications. For example, it is commonly used as a single dose for surgical prophylaxis (prevention of infection before surgery) and for the treatment of uncomplicated gonorrhea.

How should Cefalogen be stored and disposed of?

Storage and Disposal Requirements

Official labeling defines specific conditions for the storage of Cefalogen (ceftriaxone) to maintain stability.

Product State Storage Condition Stability/Constraint
Unreconstituted Powder Controlled room temperature (20 C to 25 C); Protect from light; Store in original container Do not freeze; Keep out of reach of children
Reconstituted Solution Refrigerated (mathbf4 C) or Room Temperature (mathbf25 C) Limited stability: up to 10 days refrigerated or 24 hours at room temperature

Disposal must adhere to regulatory guidelines to prevent environmental contamination. Unused or expired Cefalogen must be disposed of according to local requirements for pharmaceutical waste. The product must not be discarded via household waste or wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cefalogen found in:

A-Z Index: